Montelukast and fluticasone significantly (P = 0.011) reduced peripheral blood eosinophil counts compared with salmeterol and fluticasone.

In adult studies, montelukast reduced sputum eosinophils and attenuated early and late phase allergen-induced reactions.

There is also reported success with use of a drug (Montelukast) that stops the production of the inflammatory leukotrienes associated with EC.